Abstract | BACKGROUND: METHODS: One hundred and four patients with surgically resected NSCLC were evaluated as one institutional cohort. Tumour sections were stained by immunohistochemistry (IHC) for ASCT2, Ki-67, phospho-mTOR ( mammalian target of rapamycin), and CD34 to assess the microvessel density. Two hundred and four patients with NSCLC were also validated by IHC from an independent cohort. RESULTS: ASC amino-acid transporter 2 was expressed in 66% of patients, and was closely correlated with disease stage, lymphatic permeation, vascular invasion, CD98, cell proliferation, angiogenesis, and mTOR phosphorylation, particularly in patients with adenocarcinoma (AC). Moreover, two independent cohorts confirmed that ASCT2 was an independent marker for poor outcome in AC patients. CONCLUSIONS: ASC amino-acid transporter 2 expression has a crucial role in the metastasis of pulmonary AC, and is a potential molecular marker for predicting poor prognosis after surgery.
|
Authors | K Shimizu, K Kaira, Y Tomizawa, N Sunaga, O Kawashima, N Oriuchi, H Tominaga, S Nagamori, Y Kanai, M Yamada, T Oyama, I Takeyoshi |
Journal | British journal of cancer
(Br J Cancer)
Vol. 110
Issue 8
Pg. 2030-9
(Apr 15 2014)
ISSN: 1532-1827 [Electronic] England |
PMID | 24603303
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Amino Acid Transport System ASC
- Biomarkers, Tumor
- Minor Histocompatibility Antigens
- SLC1A5 protein, human
|
Topics |
- Aged
- Aged, 80 and over
- Amino Acid Transport System ASC
(genetics)
- Biomarkers, Tumor
(genetics)
- Carcinoma, Non-Small-Cell Lung
(genetics, pathology, surgery)
- Female
- Gene Expression Regulation, Neoplastic
- Humans
- Male
- Middle Aged
- Minor Histocompatibility Antigens
- Neoplasm Metastasis
(genetics)
- Prognosis
|